Your session is about to expire
← Back to Search
rhPSMA 7.3 PET/MRI Scan for Recurrent Prostate Cancer
Study Summary
This trial will test whether a PET/MRI scan using a radioactive tracer agent can help detect recurrent prostate cancer in patients with increasing PSA levels following surgery.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a severe fear of enclosed spaces (claustrophobia).I am a man and older than 18.You have had an allergic reaction to the contrast agent used in MRI scans before.My treatment plan includes additional radiation, possibly with hormone therapy.I stopped my hormone therapy for cancer more than 12 weeks ago.I am scheduled for a CT or MRI scan with contrast, or a PET scan, within 24 hours before the PET scan.I do not speak English but can join the trial.My PSA levels have been above 0.2 twice, indicating a possible cancer recurrence.I had surgery to remove my prostate due to cancer.You have difficulties with thinking, memory, or understanding.
- Group 1: Diagnostic (F-18 rhPSMA-7.3, PET/MRI)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the total number of participants chosen to take part in this clinical trial?
"Affirmative. Evidence from clinicaltrials.gov confirm that this research trial, first published on August 4th 2021, is actively recruiting patients. 25 participants must be gathered from a singular site to complete the study's requirements."
What hazards might be associated with Fluorine F 18 rhPSMA-7.3?
"As this is a Phase 1 trial, there is very little data available to support the safety and effectiveness of Fluorine F 18 rhPSMA-7.3; as such, it has been scored with a 1 on our scale from one to three."
Have any other experimental tests included Fluorine F 18 rhPSMA-7.3?
"As of now, 8 clinical trials are being conducted to research the effects of Fluorine F 18 rhPSMA-7.3 with no Phase 3 studies in progress. The majority of these investigations take place in Honolulu, Hawaii although 33 other sites across America are offering this medication as part of their trial program."
Are there any openings in this clinical trial at the current time?
"Data hosted on clinicaltrials.gov reveals that this medical research is currently recruiting volunteers. It was first posted on August 4th 2021 and most recently updated October 6 2022."
Share this study with friends
Copy Link
Messenger